This article is more than 5 years old. Information may no longer be current.
HCV genotype 4 patients achieved SVR12 with triple therapy
Click Here to Manage Email Alerts
CHICAGO — Hepatitis C virus genotype 4-infected patients met sustained virologic response at 12 weeks with an all-oral triple therapy of daclatasvir, asunaprevir and the non-nucleoside NS5B inhibitor BMS-791325, according to research presented at Digestive Disease Week 2014.
Researcher Tarek Hassanein, MD, of the Southern California Liver Centers, and colleagues randomly assigned 21 treatment-naive hepatitis C virus genotype 4-infected patients to either 30 mg daclatasvir, 200 mg asunaprevir, and 75 mg BMS-791325 (Bristol-Myers Squibb; n=11) twice daily or 150 mg BMS-791325 (n=10) twice daily for 12 weeks. Patients were primarily men (62%), white (91%) and noncirrhotic.
According to data, 10 of the 75-mg BMS-791325 patients achieved sustained virologic response at 12 weeks (SVR12), with the other missing patient meeting SVR24. Nine patients in the 150-mg BMS-791325 group achieved SVR12, with one patient still being followed.
There were no reports of patients experiencing virologic failure or post-treatment relapses; no serious adverse events (AE) were reported. The most common AE were headache (29%), nausea (14%) and pain (14%).
“One hundred percent of the patients with genotype-4 achieved an SVR at or after post-treatment week 12,” Hassanein said during his presentation. “There were no differences between the doses of [BMS-791325], and they were both effective.”
For more information:
Hassanein T. #763. Presented at: Digestive Disease Week 2014; May 3-6; Chicago.
Disclosure: The researchers report numerous relevant financial disclosures.